CVS Health Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
J. Joyner
Chief executive officer
US$17.8m
Total compensation
| CEO salary percentage | 6.20% |
| CEO tenure | 1yr |
| CEO ownership | 0.004% |
| Management average tenure | 2.7yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CVS Health: A Deeply Undervalued Giant Investors Keep Ignoring
Sep 25CVS Health's (NYSE:CVS) Soft Earnings Don't Show The Whole Picture
Aug 13
CVS Health (NYSE:CVS) Will Pay A Dividend Of $0.665
Apr 08CVS Health: I Don't Understand The Fuss, But The Worst Is Behind
Mar 30CVS Health (NYSE:CVS) Is Paying Out A Dividend Of $0.665
Mar 25Is CVS Health (NYSE:CVS) A Risky Investment?
Mar 07CVS Health: Incremental Improvement Best Hope For 2025 (Rating Downgrade)
Feb 26Market Might Still Lack Some Conviction On CVS Health Corporation (NYSE:CVS) Even After 25% Share Price Boost
Feb 17Earnings Beat: CVS Health Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 14CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Feb 13CVS Health Isn't Going To The Dogs
Jan 17CVS Health: An Attractive 5.8% Safe Yield For Now
Jan 10Market Cool On CVS Health Corporation's (NYSE:CVS) Earnings Pushing Shares 25% Lower
Dec 26CVS Health: When The Industry Is In Crisis, Don't Pick The Weaker Players
Dec 10There May Be Some Bright Spots In CVS Health's (NYSE:CVS) Earnings
Nov 19CVS Health: Cheap But No Signs Of Turnaround (Yet)
Nov 06CVS Health (NYSE:CVS) Has A Somewhat Strained Balance Sheet
Nov 03Why CVS’s Valuation Signals Opportunity
CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connectedCVS Health Stock Dip: Undervalued And Ready For A Turnaround
Oct 24CVS Health: Glenview's Activism Ramps Up Pressure On Management
Sep 30CVS Health: At Least There's A Valuable Lesson (Rating Downgrade)
Sep 10CVS Health Q2 Earnings: CEO's Swinging Axe May Have Ended The Bear Run
Aug 07CVS Health: A Better Investment Than Walgreens Boots Alliance
Jul 09Vltava Fund - CVS Health Corp.: Why We Sold CVS
Jul 03CVS Health: Mismanagement, Eroding Moat And Poor Momentum Make It A Sell
Jun 21The Correct Play On CVS Health
Jun 06CVS Health: Downside Movement Is Overdramatic
May 26CVS Health: Secure Dividend And Upside Potential Presents Compelling Opportunity
May 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$5b |
| Mar 31 2025 | n/a | n/a | US$5b |
| Dec 31 2024 | US$18m | US$1m | US$5b |
Compensation vs Market: J.'s total compensation ($USD17.81M) is above average for companies of similar size in the US market ($USD13.50M).
Compensation vs Earnings: Insufficient data to compare J.'s compensation with company performance.
CEO
J. Joyner (60 yo)
Mr. J. David Joyner is President, CEO & Director of CVS Health Corporation from October 17, 2024 and served as Executive Vice President from January 30, 2023 to October 17, 2024 and was President of CVS Ca...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | US$305.00k | 0.00033% $ 326.0k | |
| President | 1yr | US$17.81m | 0.0041% $ 4.1m | |
| EVP of Ventures and Chief Experience & Technology Officer | 3.3yrs | US$11.36m | 0.0050% $ 5.0m | |
| Executive VP & Chief People Officer | 1.1yrs | US$6.85m | no data | |
| Executive VP & Group President | 3.9yrs | US$13.27m | 0.0048% $ 4.7m | |
| Executive VP & CFO | less than a year | no data | 0% $ 0 | |
| Senior VP | 6.9yrs | no data | 0.00089% $ 879.3k | |
| Executive VP & Chief Compliance Officer | no data | no data | no data | |
| Executive VP | 2.7yrs | US$11.89m | 0.0017% $ 1.7m | |
| Head of Markets of Healthcare Benefits | 3.7yrs | no data | no data | |
| Chief Sustainability Officer & Senior VP of Corporate Social Responsibility | 2.7yrs | no data | no data | |
| President of Health Care Delivery & Executive VP | 3.4yrs | no data | 0.00088% $ 869.5k |
Experienced Management: CVS's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | US$305.00k | 0.00033% $ 326.0k | |
| President | 1yr | US$17.81m | 0.0041% $ 4.1m | |
| Independent Director | 2yrs | US$335.00k | 0.00089% $ 879.3k | |
| Independent Director | less than a year | US$167.50k | 0% $ 0 | |
| Independent Director | 14.8yrs | US$335.00k | 0.0018% $ 1.7m | |
| Independent Director | 18.6yrs | US$355.00k | 0.0099% $ 9.8m | |
| Independent Director | 10.6yrs | US$335.00k | 0.00023% $ 227.2k | |
| Independent Director | less than a year | US$167.50k | 0.00095% $ 938.6k | |
| Independent Director | 6.9yrs | US$360.00k | 0.0031% $ 3.1m | |
| Independent Director | 3.1yrs | US$348.33k | 0.00094% $ 928.7k | |
| Director | less than a year | US$167.50k | 0.00034% $ 335.9k | |
| Lead Independent Director | 1.9yrs | US$335.00k | 0.0036% $ 3.6m |
Experienced Board: CVS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/12 22:11 |
| End of Day Share Price | 2025/10/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CVS Health Corporation is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Samuel Hudson | Atlantic Equities LLP |